The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2021 | GEMSTONE-301: sugemalimab versus placebo for phase III NSCLC
Yi-Long Wu, MD, FACS, Guangdong General Hospital, Guangzhou, China, gives an overview of the rationale, design and results of the randomized, double-blind, placebo-controlled Phase III GEMSTONE-301 clinical trial (NCT03728556) evaluating sugemalimab, an anti-PD-L1 monoclonal antibody, as a consolidation treatment in patients with stage III non-small cell lung cancer (NSCLC) who have not progressed on concurrent or sequential chemoradiotherapy (CRT). Concurrent CRT is the current standard of care for patients with unresectable stage III NSCLC. Nevertheless, up to 50% of patients cannot tolerate this treatment and they are therefore given sequential CRT. The study met its primary endpoint of progression-free survival (PFS) and there was a trend towards a benefit in overall survival (OS) for patients receiving sugemalimab. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.
Disclosures
Dr Wu reports advisory services for AstraZeneca, Boehringer Ingelheim, Novartis, Takeda; personal fees from AstraZeneca, Beigene, Boehringer Ingelheim, BMS, Eli Lilly, MSD, Pfizer, Roche, Sanofi; grants from AstraZeneca, Boehringer Ingelheim, BMS, Hengrui, and Roche, outside the submitted work.
